Inspire Medical Systems, Inc. (NYSE: INSP) is highlighted as one of the top oversold NYSE stocks to buy now. Analyst David Rescott maintained a Buy rating on INSP with a price target of $150.00 after the company’s fiscal Q2 2025 earnings release on August 4.

In fiscal Q2 2025, Inspire Medical Systems, Inc. (NYSE: INSP) reported $217.1 million in revenue, an 11% increase from the same quarter last year. The gross margin for the quarter was 84.0%, with a net loss of $3.6 million. Adjusted net income was $13.3 million, and adjusted diluted earnings per share were $0.45.

Inspire Medical Systems, Inc. (NYSE: INSP) has initiated the full launch of the Inspire V neurostimulation system in the United States. The company specializes in developing and commercializing innovative, minimally invasive solutions for obstructive sleep apnea, offering Inspire therapy with implantable components and a remote control.

While INSP shows investment potential, other AI stocks may offer greater upside with less downside risk. For an undervalued AI stock that could benefit from Trump-era tariffs and onshoring trends, check out the free report on the best short-term AI stock.

Source: Insider Monkey.

Read more at Yahoo Finance: Robert W. Baird Remains a Buy on Inspire Medical Systems (INSP)